BioSpace News Archive

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE Rule”), an equity inducement award to Dr. Paul Moore, Zymeworks’ new Chief Scientific Officer.

The global Point-of-Care Glucose Testing market size is expected to be worth around US$ 6,217.90 million by 2030 from valued at US$ 10.05 million in 2020 and is anticipated to grow at a CAGR of 3.85% from 2021 to 2030.

RemSleep Holdings Inc. announces the company has formally retained a new Senior Director for Regulatory Compliance and Regulatory submissions to gain FDA clearance to market the company’s medical device respiratory products.

Biogénesis Bagó announced its consortium with the South Korean company FVC for the construction of a world class site that will produce up to 100 million doses of FMD vaccine per year.

Veltex Corporation (OTCQB:VLXC) (“Veltex”), a Health and Wellness Acquisition Firm, is pleased to announce its successful uplisting from the OTC Pink Market to the OTCQB® Venture Market (the “OTCQB”) effective for trading July 25, 2022 at the open.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the closing of an underwritten public offering of 13,225,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions.

Stevanato Group S.p.A. announced that it will issue financial results for the second quarter of 2022 on Thursday, August 4, 2022, at 6:30 a.m. Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. on Thursday, August 4, 2022 to discuss results.

IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th.